Cargando…

Modeling‐Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab

Denosumab is associated with continued gains in hip and spine BMD with up to 10 years of treatment in postmenopausal women with osteoporosis. Despite potent inhibition of bone remodeling, findings in nonhuman primates suggest modeling‐based bone formation (MBBF) may persist during denosumab treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dempster, David W, Chines, Arkadi, Bostrom, Mathias P, Nieves, Jeri W, Zhou, Hua, Chen, Li, Pannacciulli, Nico, Wagman, Rachel B, Cosman, Felicia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328280/ https://www.ncbi.nlm.nih.gov/pubmed/32163613 http://dx.doi.org/10.1002/jbmr.4006

Ejemplares similares

Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
por: Geusens, Piet, et al.
Publicado: (2022)

No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients
por: Misof, Barbara M., et al.
Publicado: (2020)

Effect of Denosumab on Femoral Periprosthetic BMD and Early Femoral Stem Subsidence in Postmenopausal Women Undergoing Cementless Total Hip Arthroplasty
por: Aro, Hannu T, et al.
Publicado: (2019)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum
por: Bukata, Susan V., et al.
Publicado: (2021)

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review
por: Kendler, David L., et al.
Publicado: (2021)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial
por: Chavassieux, Pascale, et al.
Publicado: (2019)

Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease
por: Broadwell, Aaron, et al.
Publicado: (2020)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

A Pooled Analysis of Fall Incidence From Placebo‐Controlled Trials of Denosumab
por: Chotiyarnwong, Pojchong, et al.
Publicado: (2020)

Denosumab and atypical femoral fractures
por: Aspenberg, Per
Publicado: (2014)

Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses
por: Cosman, Felicia, et al.
Publicado: (2022)

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA‐HD Study Extension
por: Ramchand, Sabashini K., et al.
Publicado: (2022)

Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer
por: Silver, David S.
Publicado: (2010)

The influence of lifestyle, menstrual function and oral contraceptive use on bone mass and size in female military cadets
por: Ruffing, Jamie A, et al.
Publicado: (2007)

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023)

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
por: Adachi, Jonathan D., et al.
Publicado: (2017)

Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study
por: Lipplaa, Astrid, et al.
Publicado: (2023)

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
por: Ferrari, S, et al.
Publicado: (2019)

Observations following discontinuation of long-term denosumab therapy
por: McClung, M. R., et al.
Publicado: (2017)

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
por: Brown, Jacques P, et al.
Publicado: (2013)

Periprosthetic joint infections in femoral neck fracture patients treated with hemiarthroplasty – should we use antibiotic-loaded bone cement?
por: Crego-Vita, Diana, et al.
Publicado: (2022)

An Atraumatic Femoral Fracture in a Patient with Rheumatoid Arthritis and Osteoporosis Treated with Denosumab
por: Villiers, J., et al.
Publicado: (2013)

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies
por: Kendler, D. L., et al.
Publicado: (2018)

Ten‐Year Simulation of the Effects of Denosumab on Bone Remodeling in Human Biopsies
por: Tourolle, Duncan C, et al.
Publicado: (2021)

Atypical femoral fractures bilaterally in a patient receiving denosumab
por: Drampalos, Efstathios, et al.
Publicado: (2014)

Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study
por: Nakatsukasa, Katsuhiko, et al.
Publicado: (2018)

Sarcopenia in male patients with head and neck cancer receiving chemoradiotherapy: a longitudinal pilot study
por: Chauhan, Namrata S., et al.
Publicado: (2020)

The dilemma of denosumab: Salvage of a femoral head giant cell tumour
por: Gaston, Czar Louie, et al.
Publicado: (2014)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Previously unexplored etiology for femoral head necrosis: Metagenomics detects no pathogens in necrotic femoral head tissue
por: Liu, Chao, et al.
Publicado: (2022)

Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects
por: Singh, Dave, et al.
Publicado: (2015)

Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis‡
por: Xue, Fei, et al.
Publicado: (2013)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial
por: Saag, Kenneth G., et al.
Publicado: (2019)

Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab
por: Austin, Daniel C, et al.
Publicado: (2017)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

Safety and Comfort of an Innovative Drug Delivery Device in Healthy Subjects
por: Bertens, Christian J. F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ce1e1pmj6rnciju4p5hbujcrbg